Veterinary Medicines

Tribex 10 % Oral Suspension for Cattle

Authorised
  • Triclabendazole
Download as PDF

Product identification

Medicine name:
Tribex 10 % Oral Suspension for Cattle
Tribex 10% suspensie voor oraal gebruik voor runderen
Active substance:
  • Triclabendazole
Target species:
  • Cattle
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Triclabendazole
    100.00
    milligram(s)
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Oral suspension
Withdrawal period by route of administration:
  • Oral use
    • Cattle
      • Meat and offal
        56
        day
      • Milk
        84
        hour
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP52AC01
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Netherlands
Package description:
  • Pack sizes:1L pack contains 0.8L of product,Container: High density polyethyleneClosure: Copolymer polypropylene with tamper evident sealCap Liner: Polyfaced Steran WadSpout: Polypropylene
  • Pack sizes:2.5L pack contains 2.2L of product,Container: High density polyethyleneClosure: Copolymer polypropylene with tamper evident sealCap Liner: Polyfaced Steran WadSpout: Polypropylene
  • Pack sizes:2.5L pack contains 2.5L of product,Container: High density polyethyleneClosure: Copolymer polypropylene with tamper evident sealCap Liner: Polyfaced Steran WadSpout: Polypropylene
  • Pack sizes:5L pack contains 5L of productContainer: High density polyethyleneClosure: Copolymer polypropylene with tamper evident sealCap Liner: Polyfaced Steran WadSpout: Polypropylene
  • Pack sizes:7.5L pack consisting of 2.5L & 5L packsContainer: High density polyethyleneClosure: Copolymer polypropylene with tamper evident sealCap Liner: Polyfaced Steran WadSpout: Polypropylene

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Generic application (Article 13(1) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Chanelle Pharmaceuticals Manufacturing Limited
Marketing authorisation date:
Manufacturing sites for batch release:
  • Chanelle Pharmaceuticals Manufacturing Limited
Responsible authority:
  • Medicines Evaluation Board
Authorisation number:
  • REG NL 10003
Date of authorisation status change:
Reference member state:
  • Ireland
Procedure number:
  • IE/V/0130/001
Concerned member states:
  • Netherlands
  • United Kingdom (Northern Ireland)

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 26/01/2022
Download

Summary of Product Characteristics

English (PDF)
Published on: 3/05/2024
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."